NCT07468916 2026-03-13
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
Jonsson Comprehensive Cancer Center
Phase 2 Not yet recruiting
Clinical Trials
6 trialsNCT04629508 2025-09-02
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
Incyte Corporation
Phase 2 Completed
NCT05482971 2025-08-13
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
PharmaEssentia
Phase 2 Active not recruiting
NCT05005182 2024-09-19
Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
Mayo Clinic
Phase 2 Terminated
NCT01998828 2020-04-20
Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
Sierra Oncology LLC - a GSK company
Phase 2 Terminated
NCT02125318 2017-02-27
A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders
Galena Biopharma, Inc.
Phase 2 Completed